therapeuticЮжно-Российский журнал терапевтической практикиSouth Russian Journal of Therapeutic Practice2712-8156РостГМУ10.21886/2712-8156-2022-3-4-32-39therapeutic-315Research ArticleОБЗОРЫREVIEWSГепаторенальный синдром: современные представления о лечении (часть III)Hepatorenal syndrome: new insights about treatment (part III)https://orcid.org/0000-0002-5754-4418КрутиковЕ. С.KrutikovE. S.

Крутиков Евгений Сергеевич, д.м.н., проф., зав. кафедрой пропедевтики внутренней медицины

Симферополь

Evgeniy S. Krutikov, Dr. Sci. (Med.), Professor, Head of Department of Propedeutics of Internal

Simferopol

nephrostar@yandex.ruhttps://orcid.org/0000-0002-5100-1535ВостриковаА. Н.VostrikovaA. N.

Вострикова Александра Николаевна, студент кафедры внутренней медицины №1

Симферополь

Aleksandra N. Vostrikova, student, Department of Internal Medicine No. 1

Simferopol

ip4ne@mail.ruhttps://orcid.org/0000-0002-1354-095XКрутиковС. Н.KrutikovS. N.

Крутиков Сергей Николаевич, д.м.н., профессор кафедры внутренней медицины №2

Симферополь

Segey N. Krutikov, Dr. Sci. (Med.), Professor, Department of Internal Medicine No. 2

Simferopol

krutikov05@yandex.ruИнститут «Медицинская академия имени С. И. Георгиевского» ФГАОУ ВО «Крымский федеральный университет им. В. И. Вернадского»РоссияMedical Academy named after S. I. Georgievsky of Vernadsky CFURussian FederationИнститут «Медицинская академия имени С. И. Георгиевского» ФГАОУ ВО «Крымский федеральный университет им. В. И. ВернадскогоРоссияMedical Academy named after S. I. Georgievsky of Vernadsky CFURussian Federation202230122022343239Copyright © Крутиков Е.С., Вострикова А.Н., Крутиков С.Н., 20222022Крутиков Е.С., Вострикова А.Н., Крутиков С.Н.Krutikov E.S., Vostrikova A.N., Krutikov S.N.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.therapeutic-j.ru/jour/article/view/315

Гепаторенальный синдром — распространённое и серьёзное осложнение у пациентов с циррозом печени, приводящее к прогрессированию основного заболевания и высокой смертности. Ведение пациентов с гепаторенальным синдромом требует систематического подхода. Несмотря на то, что фармакологические методы лечения продемонстрировали положительное влияние на снижение смертности, идеальным вариантом лечения этого синдрома является трансплантация печени с трансплантацией почек. Необходимы дальнейшие исследования для оптимизации фармакологических и немедикаментозных подходов к лечению гепаторенального синдрома. Проведён анализ обзоров литературы, клинических исследований, экспериментальных исследований, клинических рекомендаций из баз данных PubMed / MedLine и eLIBRARY по семи ключевым словам, соответствующим теме обзора.

Hepatorenal syndrome is a common and serious complication in cirrhotic patients, leading to significant morbidity and mortality. Although pharmacological treatments have shown mortality benefit, the ideal hepatorenal syndrome treatment option is liver transplantation with or without simultaneous kidney transplantation. Further research is required to optimize pharmacologic and nonpharmacologic approaches to treatment. An analysis of literature reviews, clinical studies, experimental research, clinical recommendations from PubMed / Medline and ELIBRARY databases was carried out for 7 keywords according to the review topic.

цирроз печенигепаторенальный синдромлечениеобзор литературыliver сirrhosishepatorenal syndromediagnosistreatmentliterature reviewReferencesGinès P, Guevara M, Arroyo V, Rodés J. Hepatorenal syndrome. Lancet. 2003;362(9398):1819-27. doi: 10.1016/S0140-6736(03)14903-3Ginès P, Guevara M, Arroyo V, Rodés J. Hepatorenal syndrome. Lancet. 2003;362(9398):1819-27. doi: 10.1016/S0140-6736(03)14903-3El-Naggar MM, Khalil EA, El-Daker MAM, Salama MF. Bacterial DNA and its consequences in patients with cirrhosis and culture-negative, non-neutrocytic ascites. J Med Microbiol. 2008;57(Pt 12):1533-1538. doi: 10.1099/jmm.0.2008/001867-0El-Naggar MM, Khalil EA, El-Daker MAM, Salama MF. Bacterial DNA and its consequences in patients with cirrhosis and culture-negative, non-neutrocytic ascites. J Med Microbiol. 2008;57(Pt 12):1533-1538. doi: 10.1099/jmm.0.2008/001867-0Solé C, Solà E, Morales-Ruiz M, Fernàndez G, Huelin P, Graupera I, et al. Characterization of Inflammatory Response in Acute-on-Chronic Liver Failure and Relationship with Prognosis. Sci Rep. 2016;6:32341. doi: 10.1038/srep32341Solé C, Solà E, Morales-Ruiz M, Fernàndez G, Huelin P, Graupera I, et al. Characterization of Inflammatory Response in Acute-on-Chronic Liver Failure and Relationship with Prognosis. Sci Rep. 2016;6:32341. doi: 10.1038/srep32341Krag A, Bendtsen F, Henriksen JH, Møller S. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut. 2010;59(1):105-10. doi: 10.1136/gut.2009.180570Krag A, Bendtsen F, Henriksen JH, Møller S. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut. 2010;59(1):105-10. doi: 10.1136/gut.2009.180570Schneider AW, Kalk JF, Klein CP. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology. 1999;29(2):334-9. doi: 10.1002/hep.510290203Schneider AW, Kalk JF, Klein CP. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology. 1999;29(2):334-9. doi: 10.1002/hep.510290203Ginès P, Solà E, Angeli P, Wong F, Nadim MK, Kamath PS. Hepatorenal syndrome. Nat Rev Dis Primers. 2018;4(1):23. doi: 10.1038/s41572-018-0022-7. Erratum in: Nat Rev Dis Primers. 2018;4(1):33. PMID: 30213943Ginès P, Solà E, Angeli P, Wong F, Nadim MK, Kamath PS. Hepatorenal syndrome. Nat Rev Dis Primers. 2018;4(1):23. doi: 10.1038/s41572-018-0022-7. Erratum in: Nat Rev Dis Primers. 2018;4(1):33. PMID: 30213943Lange CM. Systemic inflammation in hepatorenal syndrome - A target for novel treatment strategies? Liver Int. 2019;39(7):1199-1201. doi: 10.1111/liv.14057Lange CM. Systemic inflammation in hepatorenal syndrome - A target for novel treatment strategies? Liver Int. 2019;39(7):1199-1201. doi: 10.1111/liv.14057Tujios SR, Hynan LS, Vazquez MA, Larson AM, Seremba E, Sanders CM, et al. Risk factors and outcomes of acute kidney injury in patients with acute liver failure. Clin Gastroenterol Hepatol. 2015;13(2):352-9. doi: 10.1016/j.cgh.2014.07.011Tujios SR, Hynan LS, Vazquez MA, Larson AM, Seremba E, Sanders CM, et al. Risk factors and outcomes of acute kidney injury in patients with acute liver failure. Clin Gastroenterol Hepatol. 2015;13(2):352-9. doi: 10.1016/j.cgh.2014.07.011Huelin P, Piano S, Solà E, Stanco M, Solé C, Moreira R, et al. Validation of a Staging System for Acute Kidney Injury in Patients With Cirrhosis and Association With Acuteon-Chronic Liver Failure. Clin Gastroenterol Hepatol. 2017;15(3):438-445.e5. doi: 10.1016/j.cgh.2016.09.156Huelin P, Piano S, Solà E, Stanco M, Solé C, Moreira R, et al. Validation of a Staging System for Acute Kidney Injury in Patients With Cirrhosis and Association With Acuteon-Chronic Liver Failure. Clin Gastroenterol Hepatol. 2017;15(3):438-445.e5. doi: 10.1016/j.cgh.2016.09.156Angeli P, Garcia-Tsao G, Nadim MK, Parikh CR. News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document. J Hepatol. 2019;71(4):811-822. doi: 10.1016/j.jhep.2019.07.002Angeli P, Garcia-Tsao G, Nadim MK, Parikh CR. News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document. J Hepatol. 2019;71(4):811-822. doi: 10.1016/j.jhep.2019.07.002Осипенко М.Ф., Волошина Н.Б., Шайде Н.Л. Патология почек при циррозе печени. Эффективная фармакотерапия. 2020;1(16):58–61. doi: 10.33978/2307-3586-2020-16-1-58-61Осипенко М.Ф., Волошина Н.Б., Шайде Н.Л. Патология почек при циррозе печени. Эффективная фармакотерапия. 2020;1(16):58–61. doi: 10.33978/2307-3586-2020-16-1-58-61Саварина В.А., Мицура В.М., Скуратов А.Г., Мартемьянова Л.А. Проблемы диагностики гепаторенального синдрома в практике клинициста и патологоанатома. Проблемы Здоровья и Экологии. 2020;65(3):49–55. eLIBRARY ID:44229771Саварина В.А., Мицура В.М., Скуратов А.Г., Мартемьянова Л.А. Проблемы диагностики гепаторенального синдрома в практике клинициста и патологоанатома. Проблемы Здоровья и Экологии. 2020;65(3):49–55. eLIBRARY ID:44229771Gifford FJ, Morling JR, Fallowfield JA. Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1. Aliment Pharmacol Ther. 2017;45(5):593-603. doi: 10.1111/apt.13912Gifford FJ, Morling JR, Fallowfield JA. Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1. Aliment Pharmacol Ther. 2017;45(5):593-603. doi: 10.1111/apt.13912Angeli P, Gines P, Wong F, Bernardi M, Boyer TD, Gerbes A, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut. 2015;64(4):531-7. doi: 10.1136/gutjnl-2014-308874Angeli P, Gines P, Wong F, Bernardi M, Boyer TD, Gerbes A, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut. 2015;64(4):531-7. doi: 10.1136/gutjnl-2014-308874Chancharoenthana W, Leelahavanichkul A. Acute kidney injury spectrum in patients with chronic liver disease: Where do we stand? World J Gastroenterol. 2019;25(28):3684-3703. doi: 10.3748/wjg.v25.i28.3684Chancharoenthana W, Leelahavanichkul A. Acute kidney injury spectrum in patients with chronic liver disease: Where do we stand? World J Gastroenterol. 2019;25(28):3684-3703. doi: 10.3748/wjg.v25.i28.3684Wong F. Acute kidney injury in liver cirrhosis: new definition and application. Clin Mol Hepatol. 2016;22(4):415-422. doi: 10.3350/cmh.2016.0056Wong F. Acute kidney injury in liver cirrhosis: new definition and application. Clin Mol Hepatol. 2016;22(4):415-422. doi: 10.3350/cmh.2016.0056Wong F. Diagnosing and treating renal disease in cirrhotic patients. Minerva Gastroenterol Dietol. 2016;62(3):253-66. PMID: 27096702Wong F. Diagnosing and treating renal disease in cirrhotic patients. Minerva Gastroenterol Dietol. 2016;62(3):253-66. PMID: 27096702Mandorfer M, Bota S, Schwabl P, Bucsics T, Pfisterer N, Kruzik M, et al. Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology. 2014;146(7):1680-90.e1. doi: 10.1053/j.gastro. 2014.03.005Mandorfer M, Bota S, Schwabl P, Bucsics T, Pfisterer N, Kruzik M, et al. Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology. 2014;146(7):1680-90.e1. doi: 10.1053/j.gastro. 2014.03.005Mandorfer M, Reiberger T. Beta blockers and cirrhosis, 2016. Dig Liver Dis. 2017;49(1):3-10. doi: 10.1016/j.dld.2016.09.013Mandorfer M, Reiberger T. Beta blockers and cirrhosis, 2016. Dig Liver Dis. 2017;49(1):3-10. doi: 10.1016/j.dld.2016.09.013European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406-460. doi: 10.1016/j.jhep.2018.03.024. Erratum in: J Hepatol. 2018;69(5):1207. PMID: 29653741European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406-460. doi: 10.1016/j.jhep.2018.03.024. Erratum in: J Hepatol. 2018;69(5):1207. PMID: 29653741Garcia-Martinez R, Caraceni P, Bernardi M, Gines P, Arroyo V, Jalan R. Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology. 2013;58(5):1836-46. doi: 10.1002/hep.26338Garcia-Martinez R, Caraceni P, Bernardi M, Gines P, Arroyo V, Jalan R. Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology. 2013;58(5):1836-46. doi: 10.1002/hep.26338Wong F, Jepsen P, Watson H, Vilstrup H. Un-precipitated acute kidney injury is uncommon among stable patients with cirrhosis and ascites. Liver Int. 2018;38(10):1785-1792. doi: 10.1111/liv.13738Wong F, Jepsen P, Watson H, Vilstrup H. Un-precipitated acute kidney injury is uncommon among stable patients with cirrhosis and ascites. Liver Int. 2018;38(10):1785-1792. doi: 10.1111/liv.13738Salerno F, Navickis RJ, Wilkes MM. Albumin infusion improves outcomes of patients with spontaneous bacterial peritonitis: a meta-analysis of randomized trials. Clin Gastroenterol Hepatol. 2013;11(2):123-30.e1. doi: 10.1016/j.cgh.2012.11.007Salerno F, Navickis RJ, Wilkes MM. Albumin infusion improves outcomes of patients with spontaneous bacterial peritonitis: a meta-analysis of randomized trials. Clin Gastroenterol Hepatol. 2013;11(2):123-30.e1. doi: 10.1016/j.cgh.2012.11.007Fernández J, Angeli P, Trebicka J, Merli M, Gustot T, Alessandria C, et al. Efficacy of Albumin Treatment for Patients with Cirrhosis and Infections Unrelated to Spontaneous Bacterial Peritonitis. Clin Gastroenterol Hepatol. 2020;18(4):963-973.e14. doi: 10.1016/j.cgh.2019.07.055Fernández J, Angeli P, Trebicka J, Merli M, Gustot T, Alessandria C, et al. Efficacy of Albumin Treatment for Patients with Cirrhosis and Infections Unrelated to Spontaneous Bacterial Peritonitis. Clin Gastroenterol Hepatol. 2020;18(4):963-973.e14. doi: 10.1016/j.cgh.2019.07.055Leão GS, John Neto G, Jotz RF, Mattos AA, Mattos ÂZ. Albumin for cirrhotic patients with extraperitoneal infections: A meta-analysis. J Gastroenterol Hepatol. 2019;34(12):2071-2076. doi: 10.1111/jgh.14791Leão GS, John Neto G, Jotz RF, Mattos AA, Mattos ÂZ. Albumin for cirrhotic patients with extraperitoneal infections: A meta-analysis. J Gastroenterol Hepatol. 2019;34(12):2071-2076. doi: 10.1111/jgh.14791Caraceni P, Riggio O, Angeli P, Alessandria C, Neri S, Foschi FG, et al. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. Lancet. 2018;391(10138):2417-2429. doi: 10.1016/S0140-6736(18)30840-7Caraceni P, Riggio O, Angeli P, Alessandria C, Neri S, Foschi FG, et al. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. Lancet. 2018;391(10138):2417-2429. doi: 10.1016/S0140-6736(18)30840-7Глумчер Ф.С. Возможности применения альбумина в терапии критических состояний: современное состояние проблемы. Медицина неотложных состояний. 2014;2(57):65-73. eLIBRARY ID:21692096Глумчер Ф.С. Возможности применения альбумина в терапии критических состояний: современное состояние проблемы. Медицина неотложных состояний. 2014;2(57):65-73. eLIBRARY ID:21692096China L, Skene SS, Bennett K, Shabir Z, Hamilton R, Bevan S, et al. ATTIRE: Albumin To prevenT Infection in chronic liveR failurE: study protocol for an interventional randomised controlled trial. BMJ Open. 2018;8(10):e023754. doi: 10.1136/bmjopen-2018-023754China L, Skene SS, Bennett K, Shabir Z, Hamilton R, Bevan S, et al. ATTIRE: Albumin To prevenT Infection in chronic liveR failurE: study protocol for an interventional randomised controlled trial. BMJ Open. 2018;8(10):e023754. doi: 10.1136/bmjopen-2018-023754Kamal F, Khan MA, Khan Z, Cholankeril G, Hammad TA, Lee WM, et al. Rifaximin for the prevention of spontaneous bacterial peritonitis and hepatorenal syndrome in cirrhosis: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2017;29(10):1109-1117. doi: 10.1097/MEG.0000000000000940Kamal F, Khan MA, Khan Z, Cholankeril G, Hammad TA, Lee WM, et al. Rifaximin for the prevention of spontaneous bacterial peritonitis and hepatorenal syndrome in cirrhosis: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2017;29(10):1109-1117. doi: 10.1097/MEG.0000000000000940Сливка Н.А. Сравнительная оценка эффективности вазопрессоров при гепаторенальном синдроме. Universum: медицина и фармакология. 2019;6(61):4-7. eLIBRARY ID:39168357Сливка Н.А. Сравнительная оценка эффективности вазопрессоров при гепаторенальном синдроме. Universum: медицина и фармакология. 2019;6(61):4-7. eLIBRARY ID:39168357European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. J Hepatol. 2018;69(1):154-181. doi: 10.1016/j.jhep.2018.03.018European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. J Hepatol. 2018;69(1):154-181. doi: 10.1016/j.jhep.2018.03.018Bhutta AQ, Garcia-Tsao G, Reddy KR, Tandon P, Wong F, O'Leary JG, et al. Beta-blockers in hospitalised patients with cirrhosis and ascites: mortality and factors determining discontinuation and reinitiation. Aliment Pharmacol Ther. 2018;47(1):78-85. doi: 10.1111/apt.14366Bhutta AQ, Garcia-Tsao G, Reddy KR, Tandon P, Wong F, O'Leary JG, et al. Beta-blockers in hospitalised patients with cirrhosis and ascites: mortality and factors determining discontinuation and reinitiation. Aliment Pharmacol Ther. 2018;47(1):78-85. doi: 10.1111/apt.14366Пиманов С.И., Макаренко Е.В. Лечение декомпенсированного цирроза печени. Часть II. Гепаторенальный синдром. Гастроэнтерология. Хирургия. Интенсивная терапия. Consilium Medicum. 2019;1:36–41. doi: 10.26442/26583739.2019.1.190295Пиманов С.И., Макаренко Е.В. Лечение декомпенсированного цирроза печени. Часть II. Гепаторенальный синдром. Гастроэнтерология. Хирургия. Интенсивная терапия. Consilium Medicum. 2019;1:36–41. doi: 10.26442/26583739.2019.1.190295European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53(3):397-417. doi: 10.1016/j.jhep.2010.05.004European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53(3):397-417. doi: 10.1016/j.jhep.2010.05.004Ginès P, Schrier RW. Renal failure in cirrhosis. N Engl J Med. 2009;361(13):1279-90. doi: 10.1056/NEJMra0809139. Erratum in: N Engl J Med. 2011;364(4):389. PMID: 19776409Ginès P, Schrier RW. Renal failure in cirrhosis. N Engl J Med. 2009;361(13):1279-90. doi: 10.1056/NEJMra0809139. Erratum in: N Engl J Med. 2011;364(4):389. PMID: 19776409Boyer TD, Sanyal AJ, Wong F, Frederick RT, Lake JR, O'Leary JG, et al. Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1. Gastroenterology. 2016;150(7):1579-1589.e2. doi: 10.1053/j.gastro.2016.02.026Boyer TD, Sanyal AJ, Wong F, Frederick RT, Lake JR, O'Leary JG, et al. Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1. Gastroenterology. 2016;150(7):1579-1589.e2. doi: 10.1053/j.gastro.2016.02.026Rodríguez E, Elia C, Solà E, Barreto R, Graupera I, Andrealli A, et al. Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis. J Hepatol. 2014;60(5):955-61. doi: 10.1016/j.jhep.2013.12.032. Erratum in: J Hepatol. 2014;61(2):456. PMID: 24447876Rodríguez E, Elia C, Solà E, Barreto R, Graupera I, Andrealli A, et al. Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis. J Hepatol. 2014;60(5):955-61. doi: 10.1016/j.jhep.2013.12.032. Erratum in: J Hepatol. 2014;61(2):456. PMID: 24447876Gupta K, Rani P, Rohatgi A, Verma M, Handa S, Dalal K, et al. Noradrenaline for reverting hepatorenal syndrome: a prospective, observational, single-center study. Clin Exp Gastroenterol. 2018;11:317-324. doi: 10.2147/CEG.S153858Gupta K, Rani P, Rohatgi A, Verma M, Handa S, Dalal K, et al. Noradrenaline for reverting hepatorenal syndrome: a prospective, observational, single-center study. Clin Exp Gastroenterol. 2018;11:317-324. doi: 10.2147/CEG.S153858Saif RU, Dar HA, Sofi SM, Andrabi MS, Javid G, Zargar SA. Noradrenaline versus terlipressin in the management of type 1 hepatorenal syndrome: A randomized controlled study. Indian J Gastroenterol. 2018;37(5):424-429. doi: 10.1007/s12664-018-0876-3Saif RU, Dar HA, Sofi SM, Andrabi MS, Javid G, Zargar SA. Noradrenaline versus terlipressin in the management of type 1 hepatorenal syndrome: A randomized controlled study. Indian J Gastroenterol. 2018;37(5):424-429. doi: 10.1007/s12664-018-0876-3Israelsen M, Krag A, Allegretti AS, Jovani M, Goldin AH, Winter RW, et al. Terlipressin versus other vasoactive drugs for hepatorenal syndrome. Cochrane Database Syst Rev. 2017;9(9):CD011532. doi: 10.1002/14651858.CD011532.pub2Israelsen M, Krag A, Allegretti AS, Jovani M, Goldin AH, Winter RW, et al. Terlipressin versus other vasoactive drugs for hepatorenal syndrome. Cochrane Database Syst Rev. 2017;9(9):CD011532. doi: 10.1002/14651858.CD011532.pub2Nassar Junior AP, Farias AQ, D' Albuquerque LA, Carrilho FJ, Malbouisson LM. Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systematic review and meta-analysis. PLoS One. 2014;9(9):e107466. doi: 10.1371/journal.pone.0107466Nassar Junior AP, Farias AQ, D' Albuquerque LA, Carrilho FJ, Malbouisson LM. Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systematic review and meta-analysis. PLoS One. 2014;9(9):e107466. doi: 10.1371/journal.pone.0107466Mattos ÂZ, Mattos AA, Ribeiro RA. Terlipressin versus noradrenaline in the treatment of hepatorenal syndrome: systematic review with meta-analysis and full economic evaluation. Eur J Gastroenterol Hepatol. 2016;28(3):345-51. doi: 10.1097/MEG.0000000000000537Mattos ÂZ, Mattos AA, Ribeiro RA. Terlipressin versus noradrenaline in the treatment of hepatorenal syndrome: systematic review with meta-analysis and full economic evaluation. Eur J Gastroenterol Hepatol. 2016;28(3):345-51. doi: 10.1097/MEG.0000000000000537Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007;56(9):1310-8. doi: 10.1136/gut.2006.107789Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007;56(9):1310-8. doi: 10.1136/gut.2006.107789Gane EJ, Deray G, Liaw YF, Lim SG, Lai CL, Rasenack J, et al. Telbivudine improves renal function in patients with chronic hepatitis B. Gastroenterology. 2014;146(1):138-146.e5. doi: 10.1053/j.gastro.2013.09.031Gane EJ, Deray G, Liaw YF, Lim SG, Lai CL, Rasenack J, et al. Telbivudine improves renal function in patients with chronic hepatitis B. Gastroenterology. 2014;146(1):138-146.e5. doi: 10.1053/j.gastro.2013.09.031Mathurin P, Louvet A, Duhamel A, Nahon P, Carbonell N, Boursier J, et al. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA. 2013;310(10):1033-41. doi: 10.1001/jama.2013.276300Mathurin P, Louvet A, Duhamel A, Nahon P, Carbonell N, Boursier J, et al. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA. 2013;310(10):1033-41. doi: 10.1001/jama.2013.276300Busk TM, Bendtsen F, Henriksen JH, Fuglsang S, Clemmesen JO, Larsen FS, et al. Effects of transjugular intrahepatic portosystemic shunt (TIPS) on blood volume distribution in patients with cirrhosis. Dig Liver Dis. 2017;49(12):1353-1359. doi: 10.1016/j.dld.2017.06.011Busk TM, Bendtsen F, Henriksen JH, Fuglsang S, Clemmesen JO, Larsen FS, et al. Effects of transjugular intrahepatic portosystemic shunt (TIPS) on blood volume distribution in patients with cirrhosis. Dig Liver Dis. 2017;49(12):1353-1359. doi: 10.1016/j.dld.2017.06.011Ascha M, Abuqayyas S, Hanouneh I, Alkukhun L, Sands M, Dweik RA, et al. Predictors of mortality after transjugular portosystemic shunt. World J Hepatol. 2016;8(11):520-9. doi: 10.4254/wjh.v8.i11.520Ascha M, Abuqayyas S, Hanouneh I, Alkukhun L, Sands M, Dweik RA, et al. Predictors of mortality after transjugular portosystemic shunt. World J Hepatol. 2016;8(11):520-9. doi: 10.4254/wjh.v8.i11.520Lang M, Lang AL, Tsui BQ, Wang W, Erly BK, Shen B, et al. Renal-function change after transjugular intra-hepatic portosystemic shunt placement and its relationship with survival: a single-center experience. Gastroenterol Rep (Oxf). 2020;9(4):306-312. doi: 10.1093/gastro/goaa081Lang M, Lang AL, Tsui BQ, Wang W, Erly BK, Shen B, et al. Renal-function change after transjugular intra-hepatic portosystemic shunt placement and its relationship with survival: a single-center experience. Gastroenterol Rep (Oxf). 2020;9(4):306-312. doi: 10.1093/gastro/goaa081Song T, Rössle M, He F, Liu F, Guo X, Qi X. Transjugular intrahepatic portosystemic shunt for hepatorenal syndrome: A systematic review and meta-analysis. Dig Liver Dis. 2018;50(4):323-330. doi: 10.1016/j.dld.2018.01.123Song T, Rössle M, He F, Liu F, Guo X, Qi X. Transjugular intrahepatic portosystemic shunt for hepatorenal syndrome: A systematic review and meta-analysis. Dig Liver Dis. 2018;50(4):323-330. doi: 10.1016/j.dld.2018.01.123Ginès P, Uriz J, Calahorra B, Garcia-Tsao G, Kamath PS, Del Arbol LR, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology. 2002;123(6):1839-47. doi: 10.1053/gast.2002.37073Ginès P, Uriz J, Calahorra B, Garcia-Tsao G, Kamath PS, Del Arbol LR, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology. 2002;123(6):1839-47. doi: 10.1053/gast.2002.37073Gilg S, Sparrelid E, Saraste L, Nowak G, Wahlin S, Strömberg C, et al. The molecular adsorbent recirculating system in posthepatectomy liver failure: Results from a prospective phase I study. Hepatol Commun. 2018;2(4):445-454. doi: 10.1002/hep4.1167Gilg S, Sparrelid E, Saraste L, Nowak G, Wahlin S, Strömberg C, et al. The molecular adsorbent recirculating system in posthepatectomy liver failure: Results from a prospective phase I study. Hepatol Commun. 2018;2(4):445-454. doi: 10.1002/hep4.1167Bahirwani R, Campbell MS, Siropaides T, Markmann J, Olthoff K, Shaked A, et al. Transplantation: impact of pretransplant renal insufficiency. Liver Transpl. 2008;14(5):665-71. doi: 10.1002/lt.21367Bahirwani R, Campbell MS, Siropaides T, Markmann J, Olthoff K, Shaked A, et al. Transplantation: impact of pretransplant renal insufficiency. Liver Transpl. 2008;14(5):665-71. doi: 10.1002/lt.21367Lenz K, Buder R, Kapun L, Voglmayr M. Treatment and management of ascites and hepatorenal syndrome: an update. Therap Adv Gastroenterol. 2015;8(2):83-100. doi: 10.1177/1756283X14564673Lenz K, Buder R, Kapun L, Voglmayr M. Treatment and management of ascites and hepatorenal syndrome: an update. Therap Adv Gastroenterol. 2015;8(2):83-100. doi: 10.1177/1756283X14564673Wadei HM. Patients with Hepatorenal Syndrome Should Be Dialyzed? CON. Kidney360. 2020;2(3):410-412. doi: 10.34067/KID.0006872020Wadei HM. Patients with Hepatorenal Syndrome Should Be Dialyzed? CON. Kidney360. 2020;2(3):410-412. doi: 10.34067/KID.0006872020Mindikoglu AL, Pappas SC. New Developments in Hepatorenal Syndrome. Clin Gastroenterol Hepatol. 2018;16(2):162-177.e1. doi: 10.1016/j.cgh.2017.05.041. Erratum in: Clin Gastroenterol Hepatol. 2018;16(6):988. PMID: 28602971; PMCID: PMC5831376Mindikoglu AL, Pappas SC. New Developments in Hepatorenal Syndrome. Clin Gastroenterol Hepatol. 2018;16(2):162-177.e1. doi: 10.1016/j.cgh.2017.05.041. Erratum in: Clin Gastroenterol Hepatol. 2018;16(6):988. PMID: 28602971; PMCID: PMC5831376Simonetto DA, Gines P, Kamath PS. Hepatorenal syndrome: pathophysiology, diagnosis, and management. BMJ. 2020;370:m2687. doi: 10.1136/bmj.m2687Simonetto DA, Gines P, Kamath PS. Hepatorenal syndrome: pathophysiology, diagnosis, and management. BMJ. 2020;370:m2687. doi: 10.1136/bmj.m2687Boyer TD, Sanyal AJ, Garcia-Tsao G, Blei A, Carl D, Bexon AS, et al. Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol. 2011;55(2):315-21. doi: 10.1016/j.jhep.2010.11.020Boyer TD, Sanyal AJ, Garcia-Tsao G, Blei A, Carl D, Bexon AS, et al. Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol. 2011;55(2):315-21. doi: 10.1016/j.jhep.2010.11.020Nazar A, Pereira GH, Guevara M, Martín-Llahi M, Pepin MN, Marinelli M, et al. Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 2010;51(1):219-26. doi: 10.1002/hep.23283Nazar A, Pereira GH, Guevara M, Martín-Llahi M, Pepin MN, Marinelli M, et al. Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 2010;51(1):219-26. doi: 10.1002/hep.23283Бакулин И.Г., Варламичева А.А. Асцит, спонтанный бактериальный перитонит, гепаторенальный синдром: что общего в диагностике и лечении? Терапевтический архив. 2015;87(4):77-83. doi: 10.17116/terarkh201587477-83Бакулин И.Г., Варламичева А.А. Асцит, спонтанный бактериальный перитонит, гепаторенальный синдром: что общего в диагностике и лечении? Терапевтический архив. 2015;87(4):77-83. doi: 10.17116/terarkh201587477-83

The authors declare that there are no conflicts of interest present.